Recce Pharmaceuticals Prepares for Pivotal Trials with A$15.8 Million Funding Injection

2 min read | April 24, 2025 07:00 PM AEST | By Team Kalkine Media

Recce Pharmaceuticals Prepares for Pivotal Trials with A$15.8 Million Funding Injection — Image source: shutterstock

Strategic Allocation of Funds

The funding package includes a completed A$5 million private placement and a further entitlement offer to raise up to A$10.8 million, both priced at A$0.28 per share. If fully subscribed, the offer would inject a total of A$15.8 million into Recce’s operations, an ASX healthcare stock, covering expenses well into the second quarter of FY2026.

The primary allocation of funds will support a registration-enabling Phase 3 trial targeting diabetic foot infections (DFIs) in Indonesia. Around A$5.6 million is earmarked for this study, which will be conducted at PT Siloam International Hospitals, the largest private hospital network in the country. The study is expected to begin in Q2 2025 and aims to enrol 300 patients. Interim results are anticipated by early 2026, which could pave the way for a regional launch across ASEAN nations.

Dual Market Strategy and Global Ambitions

Simultaneously, Recce is preparing a separate Phase 3 trial in Australia for treating acute bacterial skin and skin structure infections (ABSSSI), backed by A$4.6 million from the raise. Subject to Investigational New Drug (IND) approval by the US FDA, the Australian trial may extend to US sites or trigger a parallel trial stateside. The IND submission is planned for late 2025 or early 2026, aiming for market entry in 2028.

Additional allocations from the raise include A$2 million for regulatory submissions, A$2.5 million towards a US Department of Defense-supported burn wound program, and A$1.1 million for working capital and offer costs.

Strengthening the Clinical Foundation

Alongside these initiatives, Recce recently received approval to expand its ongoing Australian Phase II DFI study, allowing up to 20 new patients. Previous data showed strong clinical response rates, reinforcing the potential of R327G as a frontline treatment option.

With a clear development roadmap, strategic funding, and ongoing international collaborations, Recce Pharmaceuticals (RCE) is positioning itself to transition from clinical-stage to commercial-stage in the coming years, as pivotal trials commence and regulatory engagements progress.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.